DEFTBIOTECH, a La Trobe University-based spin-out company, has received a $1 million funding boost to progress development of a drug used to treat nail fungal disease, a condition affecting more than half a billion people globally.
Pezadeftide, which showed promise as a topical treatment for fungal nail disease during phase 1 trials, will now undergo phase 2 trials, and the company will also investigate its use in other fungal infections.
Deftbiotech co-founder Prof Marilyn Anderson said that unlike existing treatments, Pezadeftide has been shown to kill a wide range of pathogens that cause serious disease in humans and agriculture.
"With the growth in resistant fungus, there is an immediate need to develop new treatments for fungal disease," she added.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Mar 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Mar 26
